Dr Michelle Hanlon Consultant physician, Genitourinary Medicine. Olafiaklinikken, Oslo University Hospital. National Advisory Unit for STIs

Transcription

1 Dr Michelle Hanlon Consultant physician, Genitourinary Medicine Olafiaklinikken, Oslo University Hospital. National Advisory Unit for STIs

2 Truvada FDA approved PrEP 2012 Initial slow uptake now over 120,000 PREP users

3

4 on demand and daily PrEP to those at risk

5 Daily PrEP: HIV neg MSM n=544 Condomless anal sex in preceeding 3 months Start PrEP immediately n=275 Vs defer PrEP n=269 3 PrEP vs 20 deferred infected Relative reduction: 86% NNT* 13, (90% CI 9-25) (*number needed to treat) Lancet 2016; 387: 53 60

6 In PrEP group: 3 incident HIV infections 1) reactive HIV test at 4-week visit, infection thought to pre-date start of PrEP 2) reactive HIV test at 61 weeks, not prescribed study drug since enrolment visit. 3) seroconversion illness at 53 weeks; last clinic attendance was 12-week visit (prescribed 90 tablets of study drug. Findings suggest that there were no breakthrough HIV infections in participants who were taking PrEP. Lancet 2016; 387: 53 60

7 Lancet 2016; 387: 53 60

8 on demand* and daily PrEP to those at risk * on demand is also known as event driven or event based dosing

9

10 On demand PrEP n=400 HIV neg MSM/ trans women, unprotected anal sex x 2 partners in past 6 months 199 TDF/FTC, 201 placebo, f/up median 9.3 months ( ) 2 infections TDF/FTC, 14 placebo Relative Reduction 86% N Engl J Med 2015; 373:

11 2 incident HIV-1 infections in TDF/FTC group, both diagnosed at scheduled visit v 1 returned 60/60 tablets v 2 returned 58/60 tablets Study drugs not detected in plasma samples at time of HIV-1 diagnosis. deemed to be nonadherent to preexposure prophylaxis N Engl J Med 2015; 373:

12 on demand and daily PrEP to those at risk HIV-negative MSM and trans who are inconsistent in their use of condoms with casual partners or with HIV-positive partners who are not on treatment. A recent STD or use of post-exposure prophylaxis may be markers of increased risk for HIV acquisition.

13 May be considered in HIV negative heterosexual women and men who are: v Inconsistent in condom use and v Likely to have HIV positive partner not on ART

14 : PrEP : case by case 2016: full chapter on PrEP (EACS)

15 Bent Høie (right), Norwegian Minister for Health

16 Roughly translated and paraphrased: national health service grants financial support to anti-infectious drugs which can prevent general communicable infections in persons considered to be at particularly high risk of being infected in Norway

17

18 In a liberal democracy, decisions regarding the distrubution of public funds cannot be based on which interest organisations are the most adept/ best at promoting their own cause

19 Checked NOK = 243

20

21 In 2017 : 161 new infection 102 (63%) men 30 (18.6%) MSM

22 In 2016 : 220 new infections 157 (71%) were men 87 (39.5%) MSM Total 6064 diagnosed with HIV in Norway

23 Total population ca 5.2 million Population the largest urban settlements Population 2017 Change 2016/ 2017 % change 2016/2017 Oslo 988,873 13, Bergen 254, Stavangar/ Sandnes 220, Trondheim 180, Drammen 116,

24 Primarily public healthcare system Pay nominal fee per doctor-visit v 16 general practitioner, 37 specialist Cap 238: frikort Exception v pregnant, children <16yrs old v notifiable infectious disease e.g TB, HIV, Chlamydia

25 Normally (e.g. HSV treatment): pay 100% cost medicine If chronic condition : pay 39% prescription costs (up to 56 ) EXEMPT: Notifiable infectious disease (paragraph 4) v e.g. HIV, syphilis,chlamydia, shigella) v free of charge

26

27 MSM and Trans reporting condomless anal sex with several partners in the past 12 months AND highly likely to continue this behaviour Supporting factors: STI past 12 months Sex under the influence of drugs minority background

28 Heterosexuals Individual assessment Serodiscordant partner HIV VL>50 (TrASP is preferred)

29 Holistic approach including Advice regarding safer sex Regular testing for HIV and STIs Comorbidities e.g. Substance misuse, mental health should be assessed and referred as appropriate

30

31 Seniorrådgiver Øivind Nilsen

32 Largest STI clinic in Norway v Walk-in clinic v Appointment based v MSM evening clinic v Outreach National Advisory Unit for STIs

33 Centralise care in greater Oslo area Build up expertise

34 Effective hiv prevention tool period of your life 2 weeks, 2 months, 2years...

35 period of your life 2 weeks, 2 months, 2years...

36 MSM? condomless sex? condomless sex again? Blood test: HIV negative

37

38

39

40

41 Self refer or provider referral (waiting list) Recieve appointment for PrEP assessment Baseline bloods taken in advance of consultation First consultation: Nurse first, then Dr

42 Nurse 30 min Indication?

43

44

45 Nurse 30 min Indication Knowledge of PrEP Condom use Alcohol, partydrugs, chemsex, Addiciton sex, substance

46 Doctor: Contraindication? Complicating factors? Daily Vs on demand

47 Vaccinate HBV, HAV* Prescribe appropriate PrEP regime Run through adherance Tests: v Infection screen : HIV, HCV, syphilis, STI screening every visit v Safety screen : biochemistry, urinalysis** *outbreak hepatitis A in Oslo since October 2017 **2017 HIV Norwegian guidelines

48 Standard follow up post PrEP initiation 1 month: Dr 3 months: Nurse 6 months: Nurse 9 months: Nurse 12 months: Dr

49 Co morbidities Erectile dysfunction Psychological health Substance misuse Proteinuria, DM, reduced egfr, (creatin) Osteopenia, concommitant steroid use ( anabolic or otherwise)

50 to New assessment n= 346 Transfer from other practitioner n=68 (family doctor or infectious diseases specialist) Unpublished feb 2018 : Olafiaklinikken

51 New assessment n= 346 New patients 6% 3% Daily PrEP 28% 63% EBD PrEP Not indicated did not want EBD: Event based dosing or on demand

52 First visit: n=168 MSM n= 161 (96%) MSW/M/T n= 7 (4%) Median age 35, (range19-69 yrs) 64% single 90% of those in a relationship open Hanlon, Oral presentation IUSTI 2017, Helsinki

53 Sex partner past 4 weeks v Median 3, range (0-20) v Mean 4.8 partners Attend sex clubs or sauna 48% Hanlon, Oral presentation IUSTI 2017, Helsinki

54 Condom use On average ca 42% 17.9% never use condoms Previous PEP use: 19% (32/168) previous PEP, (current- 5 yrs) 5/168 PEP >2 Hanlon, Oral presentation IUSTI 2017, Helsinki

55 STI testing last 12 months average testing 2.2 per 12 months 43 (16%) no record of STI testing Hanlon, Oral presentation IUSTI 2017, Helsinki

56 NG CT MG Total Anus (LGVx1) 6 76 Pharynx Urethra Early syphilis PrEP naive: N=168 men Hep C 1 6 Hanlon, Oral presentation IUSTI 2017, Helsinki

57 PrEP naive: : N=168 men: 6-12 months follow up NG CT MG Total Anus (LGVx2) 8 83 Pharynx Urine Early syphilis Hep C 0 6 Unpublished feb 2018: Olafiaklinikken

58 N=168 PrEP Naive 4% 2% patients 7% 29% 58% none 1 episode 2 episode 3 episode >3 episode Unpublished feb 2018: Olafiaklinikken

59 16/168 (9.5%) users discontinued PreP Reason for discontinuing Prep Number of PrEP users % of PREP users Medical 4 2.4% Moved country 2 1.2% Change in risk 5 3% Unknown 5 3% Unpublished feb 2018: Olafiaklinikken

60 26% PrEP naive had a mental health diagnosis recorded at first visit Diagnosis Number Medicated Attending Psychologist Depression (54%) 1 Bipolar 3 3 ADHD 6 6 Anxeity Other Hanlon, Oral presentation IUSTI 2017, Helsinki

61

62

63 Who should do PrEP?

64 Potential Prescribers Infectious diseases? Dermatovenerology? General practitioner?

65 Tromsø: Infectious diseases (ID) Trondheim: Dermatovenerology (DV) Olafiaklinikkken: DV Ahus : ID Kristiansand ID Stavangar ID& DV Bergen ID & DV General practitioners interested and engaged throughout the country

66

67 Multicentre Evaluation Study Electronic database: v Pas answer electronic questionnaire v Provider fills in STI, HIV results, other important event App in progress

68 PrEP has been available for 1 year now Completely free of charge to those who need it Inclusion/ Exclusion Criteria Logistical challenges v Waiting time for assessment appointment (Olafiaklinikken) v Service provision outside larger cities Recent kick off mulitcentre evaluation study

69 Olafiaklinikken high risk MSM Motivation for PrEP: avoid HIV infection Co-morbidity: mental health,recreational drugs Self reported high adherance, good tolerability No incident HIV infection in our PrEP users to date

70 Frank Pettersen, ID consultant OUS Bente Magny Bergersen ID consultant OUS Erik Pettersen ID consultant A-hus Alexander Leiva ID consultant Bergen

71

72